FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAmplia Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ATX.AX
Amplia Therapeutics Limited Stock AnalysisComprehensive stock analysis for Amplia Therapeutics Limited (ATX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisATX.AX
ATX.AX
Amplia Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ATX.AX
  1. Home
  2. Stocks
  3. Amplia Therapeutics Limited

Amplia Therapeutics Limited

🇦🇺ATX.AX•ASX

Amplia Therapeutics Limited

🇦🇺ATX.AX•ASX

Your view on ATX.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Amplia Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Chris Burns
Headquarters
90 William Street, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Chris Burns
Headquarters
90 William Street, Melbourne, VIC, AU
Description

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.

The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Amplia Therapeutics Limited. Starting points for Amplia Therapeutics Limited: EPS -AUD 0.02, beta -0.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Amplia Therapeutics Limited. Amplia Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Amplia Therapeutics Limited. Trailing twelve-month EPS for Amplia Therapeutics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent YearFY Mar 2027Next YearFY Mar 2028
Avg. estimate−AUD 0.02−AUD 0.01
Low estimate−AUD 0.02−AUD 0.01
High estimate−AUD 0.02−AUD 0.01
No. of analysts11
Year-ago EPS−AUD 0.02—
Growth−40.2%—

Revenue Estimate

RevenueCurrent YearFY Mar 2027Next YearFY Mar 2028
Avg. estimateAUD 0.00AUD 9.50M
Low estimateAUD 0.00AUD 9.50M
High estimateAUD 0.00AUD 9.50M
No. of analysts01
Year-ago revenueAUD 0.00—
Growth——

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Amplia Therapeutics Limited. Amplia Therapeutics Limited has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ATX.AX20 companies
Compare ATX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
BMT.AXBeamtree Holdings LimitedHealthcareMedical - Healthcare Information Services—
CYC.AXCyclopharm LimitedHealthcareMedical - Devices—
CYP.AXCynata Therapeutics LimitedHealthcareBiotechnology—
GSS.AXGenetic Signatures LimitedHealthcareMedical - Diagnostics & Research—
IPD.AXImpediMed LimitedHealthcareMedical - Devices—
M7T.AXMach7 Technologies LimitedHealthcareMedical - Healthcare Information Services—
MX1.AXMicro-X LimitedHealthcareMedical - Devices—
PIQ.AXProteomics International Laboratories Ltd.HealthcareMedical - Care Facilities—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$65.1M
POLBFPoolbeg Pharma PLCHealthcareOTC$46.6M
PPBTPurple Biotech Ltd.HealthcareNASDAQ$236,124
PPCBPropanc Biopharma Inc. Common StockHealthcareNASDAQ$1.8M
PPTDFPeptiDream Inc.HealthcareOTC$1.1B
PRAXPraxis Precision Medicines, Inc.HealthcareNASDAQ$8.5B
PREDQPredictive Discovery LimitedHealthcareOTC$2,996
PREV.CNPreveCeutical Medical Inc.HealthcareCNQ$11.7M
PRLDPrelude Therapeutics IncorporatedHealthcareNASDAQ$191.0M
PRMEPrime Medicine, Inc.HealthcareNASDAQ$694.9M
PRNAFAlterity Therapeutics LimitedHealthcareOTC$109.8M
PROKProKidney Corp.HealthcareNASDAQ$349.7M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Amplia Therapeutics Limited. Coverage tracks Amplia Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Amplia Therapeutics Limited.

ATX.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1

News

Latest Market News